Replies to post #362244 on Anavex Life Sciences Corp (AVXL)

[tredenwater2]

Agree, TGD is going for the whole enchilada with each trial supporting the results backwards and forwards applying endpoint efficacy that correlates across different diseases. I believe thats whats holding up the new rare disease ph 3 trial.

Crossing t’s and dotting all the i’s.